Targeting cancer with small molecule kinase inhibitors - PubMed (original) (raw)

Review

doi: 10.1038/nrc2559.

Affiliations

• PMID: 19104514
• DOI: 10.1038/nrc2559

Review

Targeting cancer with small molecule kinase inhibitors

Jianming Zhang et al. Nat Rev Cancer. 2009 Jan.

Abstract

Deregulation of kinase activity has emerged as a major mechanism by which cancer cells evade normal physiological constraints on growth and survival. To date, 11 kinase inhibitors have received US Food and Drug Administration approval as cancer treatments, and there are considerable efforts to develop selective small molecule inhibitors for a host of other kinases that are implicated in cancer and other diseases. Herein we discuss the current challenges in the field, such as designing selective inhibitors and developing strategies to overcome resistance mutations. This Review provides a broad overview of some of the approaches currently used to discover and characterize new kinase inhibitors.

PubMed Disclaimer

Similar articles

• Small molecule kinase inhibitors as anti-cancer therapeutics.
  Chahrour O, Cairns D, Omran Z. Chahrour O, et al. Mini Rev Med Chem. 2012 May;12(5):399-411. doi: 10.2174/138955712800493915. Mini Rev Med Chem. 2012. PMID: 22303944 Review.
• Targeting cancer with kinase inhibitors.
  Gross S, Rahal R, Stransky N, Lengauer C, Hoeflich KP. Gross S, et al. J Clin Invest. 2015 May;125(5):1780-9. doi: 10.1172/JCI76094. Epub 2015 May 1. J Clin Invest. 2015. PMID: 25932675 Free PMC article. Review.
• Factors underlying sensitivity of cancers to small-molecule kinase inhibitors.
  Jänne PA, Gray N, Settleman J. Jänne PA, et al. Nat Rev Drug Discov. 2009 Sep;8(9):709-23. doi: 10.1038/nrd2871. Epub 2009 Jul 24. Nat Rev Drug Discov. 2009. PMID: 19629074 Review.
• Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance.
  Bixby D, Talpaz M. Bixby D, et al. Hematology Am Soc Hematol Educ Program. 2009:461-76. doi: 10.1182/asheducation-2009.1.461. Hematology Am Soc Hematol Educ Program. 2009. PMID: 20008232 Review.
• Protein kinases: From targets to anti-cancer drugs.
  Cruzalegui F. Cruzalegui F. Ann Pharm Fr. 2010 Jul;68(4):254-9. doi: 10.1016/j.pharma.2010.03.007. Epub 2010 May 27. Ann Pharm Fr. 2010. PMID: 20637357 Review.

Cited by

• Discovery of pyrazole-based analogs as CDK2 inhibitors with apoptotic-inducing activity: design, synthesis and molecular dynamics study.
  Ali GME, Ewida MA, Elmetwali AM, Ewida HA, George RF, Mahmoud WR, Ismail NSM, Ahmed MS, Georgey HH. Ali GME, et al. RSC Adv. 2024 Oct 29;14(47):34537-34555. doi: 10.1039/d4ra06500j. eCollection 2024 Oct 29. RSC Adv. 2024. PMID: 39479486 Free PMC article.
• Reverse Phase Protein Arrays for Compound Profiling.
  Moerke N, Fallahi-Sichani M. Moerke N, et al. Curr Protoc Chem Biol. 2016 Sep 13;8(3):179-196. doi: 10.1002/cpch.9. Curr Protoc Chem Biol. 2016. PMID: 27622568 Free PMC article.
• KIDFamMap: a database of kinase-inhibitor-disease family maps for kinase inhibitor selectivity and binding mechanisms.
  Chiu YY, Lin CT, Huang JW, Hsu KC, Tseng JH, You SR, Yang JM. Chiu YY, et al. Nucleic Acids Res. 2013 Jan;41(Database issue):D430-40. doi: 10.1093/nar/gks1218. Epub 2012 Nov 28. Nucleic Acids Res. 2013. PMID: 23193279 Free PMC article.
• Phosphatidylinositol 3-Kinase/AKT Pathway Inhibition by Doxazosin Promotes Glioblastoma Cells Death, Upregulation of p53 and Triggers Low Neurotoxicity.
  Gaelzer MM, Coelho BP, de Quadros AH, Hoppe JB, Terra SR, Guerra MC, Usach V, Guma FC, Gonçalves CA, Setton-Avruj P, Battastini AM, Salbego CG. Gaelzer MM, et al. PLoS One. 2016 Apr 28;11(4):e0154612. doi: 10.1371/journal.pone.0154612. eCollection 2016. PLoS One. 2016. PMID: 27123999 Free PMC article.
• Role of ABL family kinases in cancer: from leukaemia to solid tumours.
  Greuber EK, Smith-Pearson P, Wang J, Pendergast AM. Greuber EK, et al. Nat Rev Cancer. 2013 Aug;13(8):559-71. doi: 10.1038/nrc3563. Epub 2013 Jul 11. Nat Rev Cancer. 2013. PMID: 23842646 Free PMC article. Review.

References

1. 1. Nat Biotechnol. 2008 Jan;26(1):127-32 - PubMed
2. 1. J Med Chem. 2008 Aug 28;51(16):4986-99 - PubMed
3. 1. Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10700-5 - PubMed
4. 1. Nat Biotechnol. 2005 Mar;23(3):329-36 - PubMed
5. 1. J Med Chem. 1997 Jul 18;40(15):2296-303 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group

• Other Literature Sources

  • The Lens - Patent Citations Database